Unravelling GABA Dysfunction in Autism: Pathophysiological Insights and Emerging Treatments.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and clinical mechanisms without new primary data or systematic search methodology
PubMed 41638634 · doi:10.1002/jdn.70103
What was done
This is a narrative review synthesizing preclinical and clinical literature on gamma-aminobutyric acid (GABA) signaling dysfunction in autism spectrum disorder (ASD). The authors examine alterations in GABA synthesis, receptor subtypes (GABA_A, GABA_B, GABA_C), transport, and metabolic enzymes, while reviewing pharmacological interventions targeting GABAergic pathways, including receptor agonists, reuptake inhibitors, and transaminase inhibitors.
What was found
The abstract reports no quantitative metrics, effect sizes, or participant numbers. Qualitatively, it reports that GABA_B receptor agonists (including arbaclofen and baclofen) demonstrate potential in improving social behavior and core ASD symptoms, whereas certain GABA-elevating agents (including vigabatrin and valproic acid) may exacerbate ASD-like features under specific conditions.
Why it matters
The review synthesizes the mechanistic rationale for targeting excitatory/inhibitory imbalance in autism, highlighting GABA_B receptor signaling as a targeted pathway for future clinical development.
Limits
As a narrative review, it presents no original empirical data, systematic review methodology, or meta-analytic pooling. The abstract does not quantify underlying study sizes or effect magnitudes, and clinical efficacy across the evaluated drug classes remains variable and unconfirmed.
Cited by
- supports Gamma-aminobutyric acid (GABA) is an endogenous substance that functions as the primary inhibitory mechanism in the brain.